Fundz

T-Therapeutics closes oversubscribed $133M Series B led by Advent Life Sciences and British Business Bank to advance first-in-class TCR bispecific therapies.

PRIVATENov 05, 2026

Amount Raised

$133 Million

Round Type

Series B

Biotechnology

Investors

BgfTencentSanofi VenturesJohnson & Johnson InnovationSamsara BiocapitalM VenturesEli Lilly And CompanySofinnova PartnersF PrimeDigitalis VenturesCambridge Innovation CapitalAdvent Life SciencesBritish Business Bank

Description

T-Therapeutics announced the closing of a $133 million Series B financing round co-led by Advent Life Sciences and British Business Bank. The round included participation from new investors Johnson & Johnson Innovation (JJDC), Samsara BioCapital, M-Ventures, and Eli Lilly, alongside all existing major shareholders including Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent, and BGF. The proceeds will fund clinical development of two first-in-class TCR-CD3 bispecific programmes in cancer and autoimmune disease. Dr

Who else raised in Biotechnology around the same time

Companies in the same sectors as T-Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
  • XTPL raised $6.5M on November 13, 2026.
  • BioWraptor raised $1.5M (Pre-Seed) on November 12, 2026.
  • PAM2L Biotechnologies raised an undisclosed amount on November 12, 2026.
  • Skribe Medical raised $1.6M (Pre-Seed) on November 12, 2026.
  • Biomatter raised $18M (Series A) on November 12, 2026.

Who to call at T-Therapeutics, and when

A new round usually means T-Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day T-Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at T-Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at T-Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

T-Therapeutics

About

T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs. We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment T-Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

3 contacts
Verified contactsTheodora H., CEO at T-Therapeutics Ltd hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for T-Therapeutics's next move

See what Strategic adds

Funding Insights

What this usually means
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach

T-Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.